Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1977 1
1978 3
1980 1
1981 1
1982 2
1983 1
1984 2
1986 1
1987 3
1988 3
1989 1
1990 4
1991 4
1992 5
1993 4
1994 7
1995 8
1996 7
1997 5
1998 2
1999 3
2000 4
2001 2
2002 4
2003 3
2004 5
2005 6
2006 5
2007 2
2008 4
2009 4
2010 3
2011 6
2012 4
2013 2
2014 7
2015 6
2016 9
2017 6
2018 10
2019 11
2020 11
2021 13
2022 12
2023 16
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study.
Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, Taveira-Gomes T, Botana M, Birkeland KI, Thuresson M, Jäger L, Sood MM, VanPottelbergh G, Tangri N; CaReMe CKD Investigators. Sundström J, et al. Among authors: karasik a. Lancet Reg Health Eur. 2022 Jun 30;20:100438. doi: 10.1016/j.lanepe.2022.100438. eCollection 2022 Sep. Lancet Reg Health Eur. 2022. PMID: 36090671 Free PMC article.
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M. Heerspink HJL, et al. Among authors: karasik a. Lancet Diabetes Endocrinol. 2020 Jan;8(1):27-35. doi: 10.1016/S2213-8587(19)30384-5. Lancet Diabetes Endocrinol. 2020. PMID: 31862149
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: karasik a. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540325 Free article. Clinical Trial.
SipNose-topiramate: a potential novel approach to binge eating management.
Kobo-Greenhut A, Zohar-Beja A, Hadar L, Itzhaki L, Karasik A, Caraco Y, Frankenthal H, Shahaf D, Ekstein D, Shichor I, Gur E. Kobo-Greenhut A, et al. Among authors: karasik a. J Eat Disord. 2023 Jun 26;11(1):102. doi: 10.1186/s40337-023-00825-9. J Eat Disord. 2023. PMID: 37365668 Free PMC article.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
214 results